Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 1,270 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $19.99, for a total value of $25,387.30. Following the sale, the director now owns 137,155 shares in the company, valued at $2,741,728.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Enliven Therapeutics Trading Down 7.4 %

Shares of NASDAQ ELVN opened at $17.30 on Thursday. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $26.00. The firm has a market capitalization of $712.76 million, a price-to-earnings ratio of -7.90 and a beta of 1.06. The business has a 50-day moving average of $16.98 and a 200-day moving average of $14.31.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.09. On average, analysts predict that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Analyst Ratings Changes

Separately, Mizuho began coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective for the company.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC purchased a new stake in Enliven Therapeutics in the first quarter worth approximately $158,000. Bank of New York Mellon Corp purchased a new stake in Enliven Therapeutics in the first quarter worth approximately $335,000. Tower Research Capital LLC TRC purchased a new stake in Enliven Therapeutics in the first quarter worth approximately $36,000. Citigroup Inc. purchased a new stake in Enliven Therapeutics in the first quarter worth approximately $247,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Enliven Therapeutics in the first quarter worth approximately $217,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.